CPIX
Cumberland Pharmaceuticals Inc
7.60$
-5.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 47.6% | 43.7% | 44.4% | 45.3% | 45.9% | 48.2% | 45.6% | 46.0% | 45.4% | 48.2% | 46.2% | 53.5% | |
| 21.1% | 22.4% | 22.8% | 22.1% | 22.8% | 23.8% | 21.6% | 23.7% | 23.1% | 14.9% | 15.5% | 6.1% | |
| 21.1% | 22.4% | 22.8% | 22.1% | 22.8% | 23.8% | 21.6% | 23.7% | 23.1% | 14.9% | 15.5% | 6.1% | |
| 14.4% | 11.9% | 13.1% | 14.8% | 14.7% | 15.5% | 15.0% | 15.2% | 15.8% | 22.1% | 20.1% | 21.3% | |
| 9.9% | 5.6% | 5.3% | 5.5% | 5.9% | 5.3% | 5.9% | 4.7% | 4.5% | 8.1% | 7.7% | 0.0% | |
| 1.0% | 1.1% | 1.1% | 1.2% | 1.2% | 1.2% | 1.3% | 1.3% | 1.4% | 1.2% | 1.3% | – | |
| 30.9% | 27.6% | 26.4% | 26.1% | 25.3% | 23.8% | 24.3% | 23.5% | 22.8% | 18.3% | 18.0% | 0.1% | |
| 59.4% | 64.2% | 66.6% | 66.8% | 68.1% | 70.2% | 59.5% | 59.2% | 60.8% | 68.1% | 70.0% | 72.8% | |
| 31.1% | 34.2% | 32.4% | 31.5% | 40.5% | 41.8% | 36.5% | 35.3% | 36.9% | 47.8% | 48.6% | 56.0% | |
| 0.4% | 0.4% | 0.4% | 0.5% | 8.3% | 7.2% | 0.5% | 0.6% | 0.6% | 0.6% | 0.7% | 0.8% | |
| 12.3% | 17.2% | 16.0% | 15.9% | 15.7% | 18.4% | 19.9% | 19.8% | 21.0% | 24.2% | 23.3% | 31.1% | |
| 14.7% | 15.6% | 19.7% | 20.5% | 13.2% | 13.5% | 7.5% | 7.7% | 8.0% | 6.8% | 7.4% | – | |
| 41.0% | 36.2% | 33.7% | 33.6% | 32.3% | 30.2% | 41.0% | 41.2% | 39.6% | 32.4% | 30.5% | 27.7% | |
| -12.8% | -21.4% | -23.8% | -26.1% | -28.7% | -31.7% | -32.5% | -34.5% | -38.5% | -34.9% | -42.4% | -54.7% | |
| 16.3% | 17.3% | 17.3% | 18.0% | 18.3% | 18.5% | 21.8% | 22.0% | 22.7% | 19.5% | 21.1% | 23.8% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.